-
Dtsch Arztebl Int: Increased risk of skin tumors and infectious diseases after organ transplantation?
Time of Update: 2022-01-23
In a retrospective study published today in Dtsch Arztebl Int, researchers selectively reviewed publications obtained through a PubMed search discussing the incidence and major risk factors of skin tumors and skin infections in immunosuppressed patients .
-
Super easy!
Time of Update: 2022-01-23
Cancer was estimated to kill 9. 6 million people in 2018, the second leading cause of death globally, after cardiovascular disease . The economic burden of cancer on patients and healthcare systems
-
JAHA: 'Viagra' found to have potentially deadly side effects, promote worsening abdominal aneurysm
Time of Update: 2022-01-23
from the University of Rochester, USA, published a research paper titled: Sildenafil (Viagra) Aggravates the Development of Experimental Abdominal Aortic Aneurysm in the Journal of the American Heart Association (JAHA) .
-
European Radiology: How to predict early temporal lobe injury after radiotherapy for nasopharyngeal carcinoma?
Time of Update: 2022-01-23
This study constructs and validates an MRI-based radiomics nomogram that combines radiomics features and clinical factors and can be used to predict RTLI in patients with nasopharyngeal carcinoma .
-
J Clin Oncol: Phase III clinical study evaluating the efficacy of PD-1 inhibitor Spartalizumab combined with Dabrafenib (dabrafenib) + Trametinib (trametinib) in the treatment of BRAF V600-mutated unresectable or metastatic melanoma
Time of Update: 2022-01-23
The 24-month progression-free survival rates were 44% (95% CI, 37 - 50) and 36% (95% CI, 30 - 42) in the two groups, respectively .
The 24-month progression-free survival rates were 44% (95% CI, 37 - 50) and 36% (95% CI, 30 - 42) in the two groups, respectively .
-
CA: Latest Cancer Statistics: U.S. Cancer Death Rates Down 32% From Peak, Lung Cancer Survival Rates Improve, Breast Cancer Incidences Rise Slowly
Time of Update: 2022-01-21
In recent years, an increasing number of lung cancer patients have been diagnosed at an early stage of the cancer, leading to a longer life expectancy .
-
The Hepatobiliary Surgery Department of the East Branch of the First Affiliated Hospital of Xi'an Jiaotong University successfully resected a huge liver tumor with a diameter of 25 cm
Time of Update: 2022-01-21
Associate Professor Sha Huanchen, director of the Hepatobiliary Surgery Department, was preparing to go to the operating room to carry out emergency treatment for a patient with a huge liver tumor.
-
European Radiology: Deep learning makes it possible to quickly classify bone tumors on plain radiographs!
Time of Update: 2022-01-21
Recently, a study published in the journal European Radiology evaluated the ability of DL in differentiating benign, malignant and intermediate bone tumors , and compared DL with the diagnostic level of radiologists for rapid and accurate clinical evaluation of bone tumors.
-
Science Advances: Zhang Xu et al. of Jiangsu University develop engineered exosomes to treat cancer
Time of Update: 2022-01-21
Science Advances Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapyThis study developed a simple and efficient engineered neutrophil-derived exosomes (N-Ex) and neutrophil-derived nanovesicles (NNV) as a safe and effective drug for tumor therapy.
-
Scientists in Nature sub-publish found that super nanoparticles other than exosomes are rich in disease biomarkers and therapeutic targets.
Time of Update: 2022-01-09
Professor Robert Coffey of Vanderbilt University Medical Center is a well-known intestinal tumor expert and is actively exploring whether the detection of Supermeres in the blood can achieve earlier diagnosis and treatment of diseases .
-
For the nation, anti-tumor article takes stock of the 2021 Anlotinib & Paimrizumab blockbuster study (part 1)
Time of Update: 2022-01-09
Efficacy and safety of anlotinib combined with docetaxel in the treatment of advanced NSCLC that has failed the previous immune checkpoint PD-1 inhibitor treatment: a review of the results of a phase I/II study: median PFS in enrolled patients It was 7.
-
The first domestic CDK4/6 inhibitor Dulceli was approved for marketing; probiotics are not good for melanoma immunotherapy?
Time of Update: 2022-01-09
Frontier: The latest version of the National Medical Insurance Catalogue took effect, Zebutinib was once again reduced in price, and the lowest mid-month treatment cost for similar BTK 01JAMA Oncol: Gonadotropin The effect of releasing hormone analogues on ovarian function in premenopausal breast cancer patients The results of studies on the use of gonadotropin releasing hormone analogues (GnRHa) to protect ovarian function have been mixed .
-
Will PD-1 inhibitors continue treatment after 1 year of advanced lung cancer?
Time of Update: 2022-01-09
CheckMate153 study Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 The CheckMate153 study is the first randomized clinical study to evaluate the duration of PD-1 inhibitor treatment .
-
Professor Xu Ruihua: Ten important advances in clinical research on digestive system tumors in 2021
Time of Update: 2022-01-09
1. PD-1 monoclonal antibody combined with chemotherapy first-line treatment significantly improves patient survival KEYNOTE-590 is a randomized, controlled, double-blind, global 3 Phase trial (73% of patients with esophageal squamous cell carcinoma [ESCC]) [1] .
-
Cancer Cell Fudan University multi-unit cooperation, Fan Jia/Zhou Hu/Gao Daming/Gao Qiang jointly draw the multi-omics molecular feature panorama of intrahepatic cholangiocarcinoma
Time of Update: 2022-01-09
On December 30, 2021, Jia Fan, Gao Qiang, Fudan University, Zhou Hu, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Gao Daming, the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, published a joint communication online in Cancer Cell entitled "Proteogenomic characterization identifies clinically relevant subgroups of" Intrahepatic cholangiocarcinoma" research paper, which used paired tumors and adjacent liver tissues from 262 patients to perform protegenomic characterization of intrahepatic cholangiocarcinoma (iCCA) .
-
The latest progress of pembrolizumab combination in the treatment of classic Hodgkin's lymphoma ASH 2021
Time of Update: 2022-01-09
Abstract number: 229 Pembrolizumab combined with ICE chemotherapy produced a high complete metabolic remission rate for relapsed/refractory classic Hodgkin’s lymphoma (cHL): a multi-institution phase II trial with a research background of approximately 30 -35% of cHL patients will prove to be refractory to first-line treatment or later relapse .
-
Prof. Zhiyong Ma: The first-line indications and comprehensive coverage of medical insurance for the advanced NSCLC of Bazaar® help NSCLC enter the "chronic disease era"
Time of Update: 2022-01-09
On January 1, 2022, China's independent innovation of PD-1 monoclonal antibody-Bezian® (Tilelizumab) combined with chemotherapy was used for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (NSCLC) The indications of the disease will enter the 2022 national medical insurance, and the disease burden of patients will be greatly reduced .
-
Breaking the siege, Yang Sen BCMA/CD3 dual antibody submitted a listing application to the FDA, Medical Mai Meng broke the news
Time of Update: 2022-01-09
The drug targets B cell maturation antigen (BCMA) and CD3, and is being developed for the treatment of relapsed or refractory (r/r) multiple myeloma .
Teclistamab is a bispecific antibody developed using Genmab DuoBody® technology that can simultaneously target T cell CD3 and multiple myeloma (MM) cell BCMA .
-
Have you seen skin metastases in rare cases of bladder cancer?
Time of Update: 2022-01-09
The prognosis of patients with skin metastases of bladder cancer is poor .
Researchers believe that the most likely mechanism for skin metastasis in this patient is the lymphatic spread of tumor cells through the lymphatic fistula .
-
Focusing on the progress of diagnosis and treatment of neuroblastoma, focusing on the landing of targeted immunotherapy-"Neuroblastoma Targeted Immunity Frontier Forum" conference report
Time of Update: 2022-01-09
Professor Xiaowen Zhai of the Children's Hospital of Fudan University stated in his opening speech that 2021 will be a special year for domestic high-risk patients with goddesses, because two GD2 targeted immunotherapy drugs have been introduced into China .
